$287.79
-0.67%
2026-09-04 13:11:59 EDT-$1.95
헬스케어
생명공학
NASDAQ
활발히 거래 중
Ligand Pharmaceuticals Incorporated는 생명공학(바이오제약) 기업으로서, 주로 제약 회사들이 전 세계적으로 새로운 치료 솔루션을 발견하고 개발하려는 노력을 지원할 수 있도록 기술을 발굴·진전시키는 데 ...
T
Todd C. Davis
Ligand Pharmaceuticals Incorporated
재임 기간 4y핵심 인물 리스크: Low
Todd Davis has proven to be a steady and strategic leader, successfully executing Ligand’s royalty-focused business model. His experience as a long-term board member ensures strategic continuity while his focus...
핵심 위험
•Concentration risk in the royalty portfolio.
•Dependence on partner success in clinical and commercial milestones.
핵심 순풍
•Scalable royalty-based business model.
•Strong track record of capital deployment and revenue growth.
T
Todd C. Davis
Ligand Pharmaceuticals Incorporated (LGND) · NASDAQ
American재임 기간 4 년비창업자 CEO핵심 인물 리스크: Low
University of Pennsylvania (MBA), Penn State University (BS)
출신 배경
A seasoned life sciences investor and board member who transitioned to CEO to sharpen Ligand's royalty-focused strategy.
어린 시절: Possesses over 30 years of operational and investment experience in the life sciences sector.
첫 기회: Career built on investment and board leadership, most notably serving on the Ligand board since 2007 before taking the helm.
CEO가 되기까지: Prior to his 2022 appointment as CEO, Davis was a long-standing director at Ligand, giving him deep, multi-year involvement in the company’s strategic transition toward a pure-play royalty model.
초기 비전: To leverage Ligand's unique royalty-based platform to maximize value through capital allocation and strategic asset acquisition.
Todd C. Davis has been an integral part of Ligand's governance since 2007. His transition to CEO in December 2022 followed a career focused on building high-growth life sciences companies. His deep familiarity with the business model, honed through years on the board, facilitated a seamless continuity in leadership while emphasizing accelerated capital deployment.
investor-turned-ceolong-tenure-board-memberstrategic-continuity
투자 관점
Todd Davis has proven to be a steady and strategic leader, successfully executing Ligand’s royalty-focused business model. His experience as a long-term board member ensures strategic continuity while his focus...
긍정 요인
Scalable royalty-based business model.
Strong track record of capital deployment and revenue growth.
핵심 리스크
Concentration risk in the royalty portfolio.
Dependence on partner success in clinical and commercial milestones.
경력
Extensive 30-year career spanning life sciences operations, venture capital, and executive leadership.
Ligand Pharmaceuticals
이니셔티브: CEO / Director
기간: 2007–Present
사건: Led shift in strategic focus as CEO; long-term board director since 2007.
BioDelivery Sciences International
이니셔티브: Director
사건: Strategic advisory roles in biotechnology.
life-sciences-veteranprivate-equityboard-governance
회사 성과
Performance is defined by growth in the royalty-aggregator business model and active capital deployment.
매출: Maintaining strong core revenue growth with 2026 guidance projecting $245M-$285M.
수익성: Focus on high-margin royalty streams; continues to show productive, scalable results.
주가: Stock performance generally aligns with the successful execution of the royalty aggregator model.
•Successfully raised 2025-2026 financial guidance.
•Increased core revenue growth by approximately 15%.
royalty-aggregatorgrowth-oriented
경영 역량
A methodical and strategic leader focusing on execution, team expansion, and clear capital allocation.
스타일: Strategic operator with an investment-led management philosophy.
Davis emphasizes clarity and commitment to the royalty model. He has demonstrated an ability to attract talent, notably expanding the business development team to capitalize on market opportunities. His leadership is marked by disciplined capital deployment and transparent investor communications.
strategic-operatorclear-communicator
자본 배분
Aggressive but disciplined capital allocation focused on acquiring high-quality, royalty-generating assets.
Focus on deploying up to $1 billion in capital to drive long-term royalty revenue.
Portfolio expansion: Continued growth in royalty revenue streams.
Davis is a proponent of leveraging Ligand’s balance sheet to acquire royalty assets, viewing the company as a leading royalty aggregator. He manages capital with an investor's eye, focusing on ROIC and asset quality to maintain long-term scalability.
capital-allocatorroyalty-strategy
자금 조달 및 파이낸싱
Efficient manager of corporate capital with a focus on internal and external financing to support acquisitions.
희석: minimal
Uses a blend of strong cash flows from royalties and disciplined capital deployment. Investor confidence is high, supported by the recurring nature of the royalty portfolio.
disciplinedstrong-balance-sheet
지배구조 및 통제
Standard public company governance; Davis holds meaningful but not controlling equity.
복수의결권 주식: 아니오
주식 클래스 상세: Common stock.
Davis has significant alignment with shareholders through meaningful personal equity ownership and regular open-market purchases, demonstrating confidence in the company's long-term outlook.
shareholder-alignment
건강 및 승계
No public concerns reported regarding health or succession readiness.
건강 상태: no public concerns
핵심 인물 리스크: Low
Davis has maintained a consistent and active leadership presence since 2022.
stable
R&D 및 기술 비전
Focus is on commercial royalty streams rather than direct R&D investment.
Minimal, as the model prioritizes existing royalty-generating assets.
High capacity for identifying and evaluating royalty assets.
The vision is centered on building a broad, diverse, and robust portfolio of royalty assets, minimizing the risk of drug development while capturing upside from successful products.
royalty-focusedrisk-averse
인재 채용
Active in expanding the executive and business development teams to sustain company growth.
Peter Renehan and Lee Brown: Expanded business development and investment team capacity.
Strong, focused on commercial and investment capabilities.
유지율: strong
Davis has successfully recruited senior talent with deep commercial experience, signaling an organizational priority on growth via business development.
talent-magnet
강점
Deep strategic expertise and disciplined capital allocation.
Strategic Insight: Long-term board experience provides deep context and strategic clarity.
Capital Discipline: Strong focus on deploying capital into high-margin royalty assets.
strategicdisciplined
약점 및 실패
Insufficient public data indicating significant weaknesses or historical failure patterns.
마케팅 및 브랜드
Focuses on positioning Ligand as a premier royalty-aggregator to investors and industry partners.
Strengthened reputation as a stable, high-margin, royalty-focused biopharma player.
Marketing efforts are primarily B2B and investor-focused, highlighting the unique, high-margin nature of the royalty model compared to traditional drug development firms. Davis is a consistent public face at investor events and conferences.
b2b-brandinvestor-relations
PR 및 커뮤니케이션
Highly active and transparent communicator, particularly with the investment community.
미디어 평판: positive
Davis maintains a positive, proactive relationship with investors, frequently explaining the nuances of the royalty business model. He is viewed as accessible and clear in his communication on earnings calls and media appearances.
transparentcommunicative
상류 / 하류 / 대체 기업